Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03869645 · ClinicalTrials.gov registry record
CAPERE Thrombectomy System Post-Market Clinical Follow Up Study
A clinical trial, sponsored by Medtronic Endovascular.
- Terminated
- Registry status
- 18
- Enrollment target
NCT03869645: Clinical Trial study, sponsored by Medtronic Endovascular.
NCT03869645 is a clinical trial that was terminated before completion, run by Medtronic Endovascular. The registered enrollment target is 18 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03869645 was terminated before completion, sponsored by Medtronic Endovascular.
- TERMINATED
- Registry status
- 18 participants
- Enrollment target
Study Summary
A prospective, single-arm, non-blinded study, intending to collect and evaluate data in up to forty (40) human subjects with acute thrombosis, treated with the CAPERE™ Thrombectomy System.
Primary Outcome
Clearance of clot and restoration of venous flow of the affected vessel as confirmed using venogram immediately post-procedure
Interventions
- DEVICE CAPERE Thrombectomy System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2019-06-01 |
| Est. Completion | 2020-08-26 |
Why NCT03869645 stopped before completion
NCT03869645 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 18 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which CAPERE Thrombectomy System is the first listed.
NCT03869645 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03869645 about?
NCT03869645 is a clinical study titled "CAPERE Thrombectomy System Post-Market Clinical Follow Up Study". A prospective, single-arm, non-blinded study, intending to collect and evaluate data in up to forty (40) human subjects with acute thrombosis, treated with the CAPERE™ Thrombectomy System.
What is the current status of trial NCT03869645?
This trial is currently terminated. The enrollment target is 18 participants. The study started on 2019-06-01. Estimated completion is 2020-08-26.
What interventions are being tested in trial NCT03869645?
The interventions under investigation include: CAPERE Thrombectomy System (DEVICE).
Who is sponsoring clinical trial NCT03869645?
This trial is sponsored by Medtronic Endovascular, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI